EudraVigilance

EudraVigilance is the European Medicines Agency's (EMA) centralized system for monitoring the safety of medicines and vaccines across the European Union. As the EU's pharmacovigilance database, it enables regulatory authorities to detect and assess safety signals across all 27 member states.

How EudraVigilance Works

EudraVigilance collects and analyzes adverse event reports from across the EU:

• Data submission: Marketing authorization holders (pharmaceutical companies) and national competent authorities submit reports
• Standardized format: Uses ICH E2B(R2) format for consistent international reporting
• Signal detection: Statistical data mining tools identify potential safety signals
• Expert review: EMA's Pharmacovigilance Risk Assessment Committee (PRAC) evaluates signals
• Regulatory action: Findings can lead to label changes, suspensions, or recalls

Public Access

The EMA provides public access to EudraVigilance data:

• Online access: Web-based query system for healthcare professionals and researchers
• Weekly reports: Summary statistics on adverse events for COVID-19 vaccines
• Periodic safety update reports: Detailed analyses submitted by pharmaceutical companies

Key COVID-19 Vaccine Assessments

EudraVigilance data has informed several EU regulatory decisions:

• AstraZeneca Vaxzevria: Identified rare TTS (thrombosis with thrombocytopenia syndrome)
• Janssen vaccine: Similar signal detection leading to warnings
• mRNA vaccines: Monitored myocarditis/pericarditis signals
• Updated guidance: Informed age recommendations and contraindications

Comparison to US Systems

• Centralized EU database vs. fragmented US reporting to VAERS/FAERS
• Mandatory company reporting vs. voluntary US system
• Direct regulatory authority to require label changes
• PRAC provides independent assessment of signals

Sources & Citations

• EMA: EudraVigilance
• ADRAC: Australian Drug Reactions Advisory Committee
• WHO: Global Pharmacovigilance